These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 30719819)

  • 1. Right ventricular pacing is associated with increased rates of appropriate implantable cardioverter defibrillator shocks.
    Arcinas LA; McIntyre WF; Farag A; Kushneriuk D; Hiebert B; Seifer CM
    Ann Noninvasive Electrocardiol; 2019 Jul; 24(4):e12636. PubMed ID: 30719819
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Eligibility of Pacemaker Patients for Subcutaneous Implantable Cardioverter Defibrillators.
    Ip JE; Wu MS; Kennel PJ; Thomas G; Liu CF; Cheung JW; Markowitz SM; Lerman BB
    J Cardiovasc Electrophysiol; 2017 May; 28(5):544-548. PubMed ID: 28185354
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Right ventricular pacing and the risk of heart failure in implantable cardioverter-defibrillator patients.
    Smit MD; Van Dessel PF; Nieuwland W; Wiesfeld AC; Tan ES; Anthonio RL; Van Erven L; Van Veldhuisen DJ; Van Gelder IC
    Heart Rhythm; 2006 Dec; 3(12):1397-403. PubMed ID: 17161779
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Dual Chamber and VVI Implantable Defibrillator (DAVID) Trial: rationale, design, results, clinical implications and lessons for future trials.
    Wilkoff BL;
    Card Electrophysiol Rev; 2003 Dec; 7(4):468-72. PubMed ID: 15071277
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Right ventricular pacing is an independent predictor for ventricular tachycardia/ventricular fibrillation occurrence and heart failure events in patients with an implantable cardioverter-defibrillator.
    Gardiwal A; Yu H; Oswald H; Luesebrink U; Ludwig A; Pichlmaier AM; Drexler H; Klein G
    Europace; 2008 Mar; 10(3):358-63. PubMed ID: 18308756
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Outcomes of defibrillator therapy in catecholaminergic polymorphic ventricular tachycardia.
    Roses-Noguer F; Jarman JW; Clague JR; Till J
    Heart Rhythm; 2014 Jan; 11(1):58-66. PubMed ID: 24120999
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of health care utilization in patients receiving implantable cardioverter-defibrillator therapies: An analysis of the managed ventricular pacing trial.
    Rickard J; Whellen D; Sherfesee L; Peterson BJ; Nahey T; Tang AS; Ellenbogen KA; Cheng A
    Heart Rhythm; 2017 Sep; 14(9):1382-1387. PubMed ID: 28385672
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Propensity score matched comparison of subcutaneous and transvenous implantable cardioverter-defibrillator therapy in the SIMPLE and EFFORTLESS studies.
    Brouwer TF; Knops RE; Kutyifa V; Barr C; Mondésert B; Boersma LVA; Lambiase PD; Wold N; Jones PW; Healey JS
    Europace; 2018 Sep; 20(FI2):f240-f248. PubMed ID: 29771327
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Survival after shock therapy in implantable cardioverter-defibrillator and cardiac resynchronization therapy-defibrillator recipients according to rhythm shocked. The ALTITUDE survival by rhythm study.
    Powell BD; Saxon LA; Boehmer JP; Day JD; Gilliam FR; Heidenreich PA; Jones PW; Rousseau MJ; Hayes DL
    J Am Coll Cardiol; 2013 Oct; 62(18):1674-1679. PubMed ID: 23810882
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reduced risk for inappropriate implantable cardioverter-defibrillator shocks with dual-chamber therapy compared with single-chamber therapy: results of the randomized OPTION study.
    Kolb C; Sturmer M; Sick P; Reif S; Davy JM; Molon G; Schwab JO; Mantovani G; Dan D; Lennerz C; Borri-Brunetto A; Babuty D
    JACC Heart Fail; 2014 Dec; 2(6):611-9. PubMed ID: 25282033
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patients upgraded to cardiac resynchronization therapy due to pacing-induced cardiomyopathy are at low risk of life-threatening ventricular arrhythmias: a long-term cause-of-death analysis.
    Barra S; Duehmke R; Providencia R; Marijon E; Boveda S; Virdee M; Heck P; Fynn S; Begley D; Grace A; Agarwal S
    Europace; 2018 Jan; 20(1):89-96. PubMed ID: 28031276
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reduction of ICD shock burden by eliminating back-up pacing induced ventricular tachyarrhythmias.
    Theis C; Mollnau H; Sonnenschein S; Konrad T; Himmrich E; Bock K; Schulz E; Kämpfner D; Gerhardt S; Quesada Ocete B; Münzel T; Rostock T
    J Cardiovasc Electrophysiol; 2014 Aug; 25(8):889-895. PubMed ID: 24654876
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of QRS Duration and Ventricular Pacing on Clinical and Arrhythmic Outcomes in Continuous Flow Left Ventricular Assist Device Recipients: A Multicenter Study.
    Gopinathannair R; Roukoz H; Trivedi JR; Cowger J; Bhan A; Ravichandran A; Bhat G; Birks EJ; Slaughter MS; Ahmed MM
    J Card Fail; 2019 May; 25(5):355-363. PubMed ID: 30797964
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of long-detection interval vs standard-detection interval for implantable cardioverter-defibrillators on antitachycardia pacing and shock delivery: the ADVANCE III randomized clinical trial.
    Gasparini M; Proclemer A; Klersy C; Kloppe A; Lunati M; Ferrer JB; Hersi A; Gulaj M; Wijfels MC; Santi E; Manotta L; Arenal A
    JAMA; 2013 May; 309(18):1903-11. PubMed ID: 23652522
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term follow-up of patients with cardiac sarcoidosis and implantable cardioverter-defibrillators.
    Betensky BP; Tschabrunn CM; Zado ES; Goldberg LR; Marchlinski FE; Garcia FC; Cooper JM
    Heart Rhythm; 2012 Jun; 9(6):884-91. PubMed ID: 22338670
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intraatrial conduction delay associated with an epicardial implantable cardioverter-defibrillator.
    Kocheril AG; Batsford WP
    J Electrocardiol; 1993 Oct; 26(4):341-5. PubMed ID: 8228723
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dual-chamber pacing or ventricular backup pacing in patients with an implantable defibrillator: the Dual Chamber and VVI Implantable Defibrillator (DAVID) Trial.
    Wilkoff BL; Cook JR; Epstein AE; Greene HL; Hallstrom AP; Hsia H; Kutalek SP; Sharma A;
    JAMA; 2002 Dec; 288(24):3115-23. PubMed ID: 12495391
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Right Ventricular Pacing Increases Risk of Appropriate Implantable Cardioverter-Defibrillator Shocks Asymmetrically: An Analysis of the ALTITUDE Database.
    Cronin EM; Jones P; Seth MC; Varma N
    Circ Arrhythm Electrophysiol; 2017 Oct; 10(10):. PubMed ID: 29030379
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term follow-up of implantable cardioverter-defibrillator for secondary prevention in chagas' heart disease.
    Martinelli M; de Siqueira SF; Sternick EB; Rassi A; Costa R; Ramires JA; Kalil Filho R
    Am J Cardiol; 2012 Oct; 110(7):1040-5. PubMed ID: 22727179
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Incidence and predictors of pacemaker-induced cardiomyopathy with comparison between apical and non-apical right ventricular pacing sites.
    Bansal R; Parakh N; Gupta A; Juneja R; Naik N; Yadav R; Sharma G; Roy A; Verma SK; Bahl VK
    J Interv Card Electrophysiol; 2019 Oct; 56(1):63-70. PubMed ID: 31363943
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.